Untitled

Abstract

The development of mucoadhesive buccal formulations has recently gained a great deal of attention. Despite several proposed solutions, drug permeability and regulated drug release via this mode of delivery remain concerns for successful therapy. Clinical uses for recent advances in nanotechnology have been examined. In addition to ensuring effective distribution, the use of nanoparticles in dosage forms for buccal administration also helps to minimize any negative effects on biological systems. To load and distribute drug-containing nanoparticles to the buccal mucosa for topical and systemic applications, several strategies have been proposed. In order to improve medication delivery or targeting, this study outlines contemporary cutting-edge approaches for using nanoparticles in dosage forms. Of give a general overview of current approaches to implementing controlled drug delivery, these technologies are categorized and discussed. All of these noteworthy results will promote novel nanoparticle-delivered dose formulations for buccal distribution in clinical settings. Overall, the buccal mucosa provides a lot of advantages for controlled pharmaceutical delivery over an extended period of time. INTRODUCTION:Several different layers of cells are located at the buccal mucosa, including stratum filamentosum, stratum distendum, stratum basale, stratum suprabasale, submucosa, and lamina propria. Because the mucosa and smooth muscle are largely static, buccal drug administration is advantageous due to patient compliance, simplicity of administration and removal, minimal enzymatic activity, and appropriateness for controlled release dose forms 1 . Drugs delivered buccally can be used for both local and systemic treatment. This kind of local therapy can maintain medication delivery at the intended spot while reducing unwanted effects.